Trials
May 21, 2024
Chiranth Bhagavan, Paul Glue, Will Evans et al.
7 citations
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in this population. Several centres have reported that one dose of the serotonergic psychedelic psilocybin, combined with therapeutic support, improves these symptoms for up to 6 months in this patient group. Drawing upon related therapeutic mechanisms,...
European Journal of Neuroscience
May 21, 2024
Nur Damla Korkmaz, Ugur Cikrikcili, Merve Akan et al.
19 citations
Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT 2A receptor activation. Lysergic...
C&EN Global Enterprise
May 20, 2024
Sarah Braner
Reunion Neuroscience , a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk Foundation's investment arm Novo Holdings. The company's lead asset, RE104, is a novel psychedelic that is being developed to treat adjustment disorder in cancer patients as well as postpartum depression. RE104 is a prodrug of 4-OH-DiPT, which acts...
American Journal of Geriatric Psychiatry
May 19, 2024
Hannes Kettner, Leor Roseman, Adam Gazzaley et al.
18 citations
OBJECTIVE: Affective symptoms such as anxiety, low mood, and loneliness are prevalent and highly debilitating symptoms among older adults (OA). Serotonergic psychedelics are currently investigated as novel interventions for affective disorders, yet little is known regarding their effects in OA. We investigated the mental health effects and psychological mechanisms of guided psychedelic group...
iScience
May 19, 2024
Andres Ort, John W Smallridge, Erich Seifritz et al.
1 citation
Serotonergic psychedelics hold promise as a treatment modality for various psychiatric disorders and are currently applied in psychedelic-assisted psychotherapy. We investigated the learning effects of the serotonin receptor agonist psilocybin in a probabilistic cue-reward task with emotional cues in the form of neutral or fearful faces, presented either consciously or subconsciously. This...
Science
May 16, 2024
Jiankun Lyu, Nicholas J. Kapolka, Ryan H. Gumpper et al.
145 citations
AlphaFold2 (AF2) models have had wide impact but mixed success in retrospective ligand recognition. We prospectively docked large libraries against unrefined AF2 models of the σ 2 and serotonin 2A (5-HT2A) receptors, testing hundreds of new molecules and comparing results with those obtained from docking against the experimental structures. Hit rates were high and similar for the experimental...
Psychiatry and Clinical Neurosciences Reports
May 16, 2024
Shunichiro Ikeda, Toshihiko Kinoshita
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various disorders, such as major depressive disorder (MDD). However, the non-medical use of these substances became rampant due to their hallucinogenic effects, leading to their classification as narcotics in numerous countries by the 1970s. Since the 1990s,...
bioRxiv Preprint Server
May 7, 2024
Victor Distefano Wiltenburg, Gabriela Morales-Lima, Aline Valéria Sousa Santos et al.
preprint
Abstract Background Ayahuasca, a psychoactive Amazonian preparation, is increasingly studied for substance-use disorders. Objectives Investigate whether oral lyophilised-ayahuasca attenuates ethanol-induced conditioned place preference (CPP) in mice and alters ΔFosB expression in nucleus accumbens (NAc). Methods Male Swiss mice received water or ayahuasca (130-1950 mg/kg, p.o.) 30 min before...
Brain
May 4, 2024
Jérôme Jeanblanc, Romain Bordy, Grégory Fouquet et al.
10 citations
Abstract The use of psilocybin to treat alcohol use disorder is very promising, but its mechanisms of action remain poorly understood. We combined behavioural, pharmacological and gene expression analyses to decipher the mechanisms of action of psilocybin, for the first time, when injected into the brain. Male Long Evans rats underwent chronic operant ethanol self-administration before testing...
Physiology
May 1, 2024
Rachel Summerfield, Trent Groenhout, Tiecheng Liu et al.
Psychedelics, including N, N, Dimethyltryptamine (DMT), are being increasingly explored for therapeutic potential to treat psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder. These and other psychiatric conditions have a bidirectional relationship with sleep patterns but the impact of psychedelics, particularly DMT, on sleep architecture is incompletely...